Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
Summary
HR9260 is a House-originated appropriations bill for Labor-HHS-Education for FY2027, placed on the Union Calendar on June 11, 2026, but not yet enacted. No specific funding levels are provided in the available data, and the legislative path remains uncertain. At this stage, the bill has no measurable near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9260 is a procedural appropriations bill, not yet law, with no specified funding amounts in the available data.
- 2.Market impact is negligible at this stage; only broad sector exposure can be assumed (Healthcare).
- 3.Investors should watch for actual enacted funding levels for HHS, particularly NIH and CMS, to assess real revenue impact on healthcare companies.
Market Implications
The bill's current procedural status—placed on the Union Calendar—indicates momentum but no certainty. No real market data on stock prices is provided, and no specific company is directly impacted by this step. The healthcare sector broadly depends on annual appropriations, but without knowing final funding amounts for NIH, CMS, or other HHS agencies, no investor should trade on this news. The SEC financial data shows large healthcare firms (e.g., UNH with $371.6B revenue, JNJ with $85.2B) but the link is too weak. The appropriate action is to monitor the bill's progress through the House and Senate.
Full Analysis
HR9260 is an appropriations bill for the Departments of Labor, Health and Human Services, and Education for fiscal year 2027. It was reported by the House Committee on Appropriations with a committee report (H. Rept. 119-696) and placed on the Union Calendar on June 11, 2026, meaning it is eligible for floor consideration. The sponsor, Rep. Aderholt (R-AL), is a senior appropriator, which lends procedural momentum, but the bill has not passed the House, the Senate, or been signed into law. No actual funding has been allocated. The money trail is purely prospective: if enacted, the bill would provide appropriated funds for HHS agencies (e.g., NIH, CDC, FDA, CMS) and education/labor programs. However, without specific dollar amounts or program-level details in the provided data, the revenue impact on any individual healthcare company is unknowable. The SEC financial data for healthcare companies (e.g., UNH, HCA, JNJ, LLY) shows their massive revenue bases, but the link to this procedural bill is too tenuous to establish a causal chain. There is no real market data provided for stock prices. The timeline: the bill must pass the House, then the Senate, and be reconciled before enactment, likely later in 2026. Until specific funding levels are known, the market implications are negligible.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.